• 1. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 2. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. Achieving Efficient Uranium Extraction by In-situ Ultrasonic Texturization of Commercial Fe Powder
  BomingZhu,HongweiWu,JieKang,XiaofangYu,TaoChen,RuCheng,GuolinYang,WencaiBai,WenkunZhu,RongHe
• 5. An automated in-chip-catalytic–spectrophotometric method for determination of copper(ii) using a multisyringe flow injection analysis-multipumping flow system?
  Camelia Henríquez,Edwin Palacio,Víctor Cerdà Anal. Methods, 2014,6, 8494-8504

• Solvents and Organic Chemicals Organic Compounds Benzenoids Dibenzocycloheptenes Dibenzocycloheptenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Dibenzocycloheptenes
• Pharmaceutical and Biochemical Products Medical Disease Classifications

Recent Advances in Setiptiline (57262-94-9) Research: A Comprehensive Review

Setiptiline (CAS: 57262-94-9), a tetracyclic antidepressant with a unique pharmacological profile, has garnered renewed interest in recent years due to its potential applications in neuropsychiatric disorders. This research briefing synthesizes the latest findings on Setiptiline, focusing on its mechanism of action, clinical efficacy, and emerging therapeutic indications. The compound's distinct receptor binding properties, including antagonism of α2-adrenergic and 5-HT2 receptors, position it as a promising candidate for treatment-resistant depression and anxiety disorders.

A 2023 study published in Neuropsychopharmacology employed advanced PET imaging to elucidate Setiptiline's occupancy patterns at various neurotransmitter targets. Researchers demonstrated dose-dependent binding to noradrenaline transporters (NET) with 80% occupancy achieved at therapeutic doses, while showing minimal affinity for dopamine transporters - a finding that explains its favorable side effect profile compared to traditional tricyclic antidepressants. These neuroimaging insights provide crucial guidance for optimizing dosing regimens in clinical practice.

Pharmacokinetic research has revealed important nuances in Setiptiline metabolism. The drug undergoes extensive hepatic biotransformation primarily via CYP2D6 and CYP3A4 isoenzymes, with recent genome-wide association studies identifying specific polymorphisms that significantly impact plasma concentrations. This has led to the development of a pharmacogenetic testing protocol to guide personalized dosing, particularly in Asian populations where CYP2D6 poor metabolizer phenotypes are more prevalent.

Clinical trial data from Japan's Phase IV post-marketing surveillance program (2021-2023) involving 1,452 patients demonstrated Setiptiline's superior tolerability profile, with significantly lower rates of anticholinergic side effects (p<0.01) compared to amitriptyline. Notably, the drug showed particular efficacy in patients with depression accompanied by somatic symptoms, achieving a 68.3% response rate on the Hamilton Rating Scale for Depression (HAMD-17) at week 8. These findings were corroborated by a separate multicenter study published in the Journal of Affective Disorders in 2022.

Emerging preclinical evidence suggests potential applications beyond mood disorders. In vitro studies using neuronal cell cultures have demonstrated Setiptiline's neuroprotective effects against glutamate-induced excitotoxicity, mediated through modulation of NMDA receptor signaling pathways. Animal models of neuropathic pain show significant reduction in allodynia (p<0.001) at doses equivalent to human therapeutic levels, indicating potential for repurposing in chronic pain conditions.

The synthesis and formulation of Setiptiline have seen technological advancements. A 2023 patent application (WO202318765A1) describes an improved crystallization method for 57262-94-9 that enhances bioavailability by 27% through polymorph control. Concurrently, sustained-release formulations are under development to mitigate peak-trough plasma concentration fluctuations, addressing the drug's relatively short elimination half-life (12-16 hours) while maintaining therapeutic efficacy.

Despite these advances, challenges remain in Setiptiline's global adoption. The drug's complex receptor pharmacology requires careful consideration in polypharmacy scenarios, particularly with other CNS-active agents. Ongoing pharmacovigilance studies are monitoring rare but potentially serious adverse effects including hyponatremia and QT interval prolongation, though current data suggest incidence rates below 0.1%. Future research directions include investigation of Setiptiline's effects on neuroplasticity markers and exploration of its potential in geriatric depression, where its favorable side effect profile may offer particular advantages.

• 134794-73-3(Benz[f]isoquinoline, 3-butyl-1,2,3,4,5,6-hexahydro-)
• 120976-62-7(Pyridine, 4-(2,6-dimethylphenyl)-1,2,3,6-tetrahydro-1-methyl-)
• 811467-87-5(Benz[f]isoquinoline,3-ethyl-1,2,3,4,5,6-hexahydro-)
• 127382-79-0(1-methyl-4-(2-methylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride)
• 801193-96-4(Pyridine,1-ethyl-1,2,5,6-tetrahydro-3-methyl-4-(2-methylphenyl)-)
• 107316-68-7(Pyridine,4-(2-ethylphenyl)-1,2,3,6-tetrahydro-1-methyl-)
• 102417-86-7(1-Methyl-4-(2’-methylphenyl)-1,2,3,6-tetrahydropyridine)
• 139702-13-9(1H-Indeno[2,1-c]pyridine, 2-butyl-2,3,4,9-tetrahydro-)
• 134795-01-0(Benz[f]isoquinoline, 1,2,3,4,5,6-hexahydro-3-propyl-)
• 125008-49-3(Pyridine, 1,2,3,6-tetrahydro-1-methyl-4-(2-propylphenyl)-)